Timing correction: Today is Tuesday, August 4, 2026. DaVita is scheduled to release 2Q26 results after the market closes today, followed by its earnings call at 5:00 p.m. ET—not tomorrow. (investors.davita.com)
DaVita enters 2Q with momentum, but also with a far more demanding setup after the stock’s sharp run this year. The core debate is no longer whether Q2 EPS beats a single-quarter consensus number; it is whether management can substantiate the components behind its raised 2026 outlook:
A constructive Q2 should therefore feature treatment growth consistent with the company’s new +0.25% to +0.50% full-year treatment-volume outlook, continued cost discipline, and confidence in the current 2026 adjusted operating-income guide of $2.15–$2.25 billion and adjusted EPS guide of $14.10–$15.20. (investors.davita.com)
In 1Q26, normalized non-acquired treatment growth was only +0.1%, but management raised full-year volume expectations to +25–50 bps. The improvement was attributed roughly half to better underlying performance—especially lower-than-expected mortality—and half to patient transfers related to Fresenius closures. Management has indicated that most of the closure-related benefit should begin to show up during 2Q. (investors.davita.com)
What investors should look for - Treatments per normalized day, rather than headline treatments, to control for calendar effects. - A clear step-up from the 1Q level of 91,889 average treatments per normalized day. - Commentary on whether the Fresenius-transfer benefit has arrived as expected and how much is sustainable into 2027. - Confirmation that lower mortality is not simply a seasonal or flu-related artifact.
Why it matters: The stock’s re-rating depends in part on confidence that dialysis volumes can transition from flat/negative organic growth toward a more durable positive trajectory. A modest beat without stronger volume evidence would be less persuasive than an in-line EPS result paired with clear volume progress.
Q2 normally benefits from deductible/co-insurance seasonality. In 1Q, U.S. dialysis revenue per treatment was $417.59, up 4.4% year over year, although management maintained its full-year expectation for only 1–2% RPT growth. The reason: a material portion of the 1Q strength was timing-related, while lower commercial mix tied to ACA exchange enrollment and reduced phosphate-binder pricing are expected to weigh more heavily later in the year. (investors.davita.com)
The year-ago comparison is also favorable mechanically: 2Q25 RPT was $404.58, with the company citing normal seasonal improvement but lower phosphate-binder volumes. (investors.davita.com)
Watch items - Whether RPT sequentially improves as seasonality would suggest. - Any change in management’s view of the roughly $40 million 2026 ACA-related headwind previously embedded in expectations. - Language around commercial mix, exchange-plan affordability/effectuation, and the pace at which incident dialysis patients shift toward Medicare coverage. - Confirmation that binder-related revenue pressure is offset by lower pharmaceutical cost, preserving operating income.
Interpretation: Strong RPT without a guide increase may be viewed as timing. The higher-quality outcome is an RPT result that supports full-year guidance and evidence that commercial mix is holding up better than feared.
DaVita’s 1Q patient-care cost per treatment was $280.11, up 3.1% year over year, driven by compensation, insurance, and medical-supply costs. Yet costs were better than management had anticipated because of productivity gains. At the same time, U.S. dialysis G&A rose 13% year over year, largely reflecting IT and technology investment. (investors.davita.com)
The key analytical issue is not whether G&A is elevated in isolation. Management’s argument is that technology and AI investment should generate returns through labor productivity, revenue-cycle performance, and clinical/operational efficiency elsewhere in the P&L.
What would be positive - Patient-care cost per treatment at or below management’s implied run-rate. - Evidence that labor productivity gains are persisting rather than merely benefiting 1Q. - No incrementally negative commentary on supply costs, tariffs, contract labor, or union activity. - A credible explanation that higher G&A is generating measurable returns.
What would concern investors - Higher labor or supply costs combined with no corresponding improvement in treatment volumes or RPT. - Incremental technology spending with no time frame or evidence of operational benefits.
IKC was a $19 million operating loss in 1Q26, versus a $46 million profit in 4Q25, reflecting lower shared savings. Management nevertheless expects a more Q4-weighted IKC contribution this year. As of March 31, it managed about 62,600 risk-based IKC patients representing approximately $5.4 billion of annualized medical spend. (investors.davita.com)
International generated $30 million of operating income in 1Q. It remains a meaningful contributor to the longer-term operating-income growth model, although quarterly results can be noisy due to reimbursements, collections, FX, and country-level factors. (investors.davita.com)
Q2 focus: Investors should want confirmation that both businesses remain on track to contribute to full-year operating-income growth—not necessarily a large quarterly upside surprise.
DaVita raised 2026 guidance after 1Q to:
| 2026 guidance | Range |
|---|---|
| Adjusted operating income | $2.15B–$2.25B |
| Adjusted diluted EPS | $14.10–$15.20 |
| Free cash flow | $1.00B–$1.25B |
The most important earnings-call question: Does management maintain, tighten, or raise this outlook?
A reiteration is likely adequate only if the company can demonstrate: - volume trending toward the upper half of its revised range; - sustained productivity; - no deterioration in ACA/commercial-mix assumptions; and - free-cash-flow conversion that supports continued buybacks.
Capital allocation is an important part of the equity story. DaVita repurchased 3.0 million shares for $403 million in 1Q and another 2.0 million shares for $302 million through May 5. However, this is occurring alongside $10.7 billion of total debt, $10.1 billion of net debt, and a 3.34x leverage ratio as of March 31. (investors.davita.com)
That balance-sheet posture is manageable within the company’s stated framework, but it makes free cash flow and interest expense important watch items—particularly if rates remain elevated.
The year-ago Q2 comparison was solid: 2Q25 revenue was $3.38 billion, adjusted operating income was $551 million, adjusted EPS was $2.95, and free cash flow was $157 million. That quarter included roughly $13.5 million of cybersecurity-related charges, so investors should be careful with simple reported-year-over-year comparisons. (investors.davita.com)
A favorable Q2 setup would be: - Positive normalized treatment growth, visibly stronger than 1Q; - Seasonal RPT improvement without a concerning commercial-mix deterioration; - Continued favorable patient-care-cost execution; - A maintained or improved 2026 operating-income/EPS outlook; - Strong repurchases and free cash flow without leverage drifting beyond the preferred range.
A disappointing setup would be: - Transfers from clinic closures coming through more slowly than expected; - Volume better only because of acquisitions or calendar, rather than organic trends; - ACA/mix pressure arriving earlier or harder than embedded in the guide; - Cost inflation offsetting productivity gains; - A lower free-cash-flow outlook or softer buyback cadence.
The cleanest bull case is a Q2 that proves the 1Q upgrade was not a one-off: better volumes, solid pricing/cost execution, and unchanged-to-higher full-year guidance. With the stock already reflecting a substantially improved outlook, the market is likely to reward confirmation of a durable volume recovery and punish any sign that the ACA/commercial-mix risk is merely being pushed into the back half.
This preview is for informational purposes only and is not investment advice.